EGFR and prostate carcinoma: Furthermore, targeting Pim-1 sensitized prostate and colon cancer cells to chemotherapeutic agents [7, 9, 10], and improved the efficacy of AKT inhibitors and epidermal growth factor receptor (EGFR) targeted therapies in prostate cancer [11, 12].